[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370247-105":59,"doc-detail-370247-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","ezh2-inhibition-enhances-the-activity-of-carboplatin-in-aggressive-variant-prostate-cancer-cell-lines","EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines","","Aggressive variant prostate cancers (AVPCs) are incurable malignancies treated palliatively with platinum-based chemotherapy, yet survival remains poor. PRC2 drives progression through histone H3 lysine 27 tri-methylation (H3K27me3), with EZH2 as its catalytic subunit. Using Nu.Q-measures for nucleosomal cf-H3K27me3, the study tests whether EZH2 inhibitors can epigenetically reprogram AVPC to improve Carboplatin efficacy, evaluated across bioinformatic cohorts, cellular and cell-free readouts, viability dose responses, and RNA-Seq gene expression changes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ezh2-inhibition-enhances-the-activity-of-carboplatin-in-aggressive-variant-prostate-cancer-cell-lines/370247/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ezh2-inhibition-enhances-the-activity-of-carboplatin-in-aggressive-variant-prostate-cancer-cell-lines/370247.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-22","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",16,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are EZH2 inhibitors considered in aggressive-variant prostate cancer?","Question",{"text":113,"@type":114},"PRC2 promotes AVPC progression through H3K27me3, and EZH2 is the PRC2 catalytic subunit. The study hypothesizes that inhibiting EZH2 can epigenetically improve response to Carboplatin.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does EZH2 inhibition affect H3K27me3 levels?",{"text":118,"@type":114},"EZH2 inhibitors reduce both cellular and cell-free nucleosomal H3K27me3 levels, linking EZH2i activity to measurable epigenetic changes.",{"name":120,"@type":111,"acceptedAnswer":121},"What is the main therapeutic outcome when combining EZH2 inhibition with Carboplatin?",{"text":122,"@type":114},"The combination is reported as promising because EZH2 inhibition significantly reduces Carboplatin IC50 and shifts gene expression toward reduced DNA repair and increased p53-dependent pro-apoptotic factors.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},370247,1790228713,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","EPIGENOMICS  \n2025, VOL. 17, NO. 3, 145–154  \n[https://doi.org/10.1080/1750191](https://doi.org/10.1080/1750191)1.2025.2453419  \n| PRELIMINARY COMMUNICATION   \u003Cbr>EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines\u003Cbr>Maryam Latarania*, Perla Puccib*, Mark Eccleston c,d, Massimiliano Manzoe, Priyadarsini Gangadharannambiara, Irene Fischetti f, Ilaria Alborellie, Vera Mongiardini g, Namra Mahmooda, Mario Paolo Colombof,\u003Cbr>Benedetto Grimaldi g, Sushila Rigasa, Shusuke Akamatsuh, Cheryl Hawkesi, Yuzhuo Wang j, Elena Jachettif and Francesco Crea a\u003Cbr>aCancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK; bDivision of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK; cBelgian Volition SPRL, Parc Scientifique Créalys, Namur, BE, Belgium; dValiRx PLC, Medicity Nottingham, Nottingham, UK; e Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland; fMolecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; gMolecular Medicine Research Line, Fondazione Istituto Italiano di Tecnologia (IIT), Genoa, Italy; hDepartment of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan; iDivision of Biomedical and Life Sciences, Lancaster University, Lancaster, UK; jDepartment of Experimental Therapeutics, BC Cancer/University of British Columbia, Vancouver, Canada |  |  |\n| --- | --- | --- |\n| \u003Cbr>ABSTRACT\u003Cbr>Background: Aggressive Variant Prostate Cancers (AVPCs) are incurable malignancies. Platinum-based chemotherapies are used for the palliative treatment of AVPC. The Polycomb Repressive Complex 2 (PRC2) promotes prostate cancer progression via histone H3 Lysine 27 tri-methylation (H3K27me3). EZH2 encodes the catalytic subunit of PRC2. A recently developed nucleosome capture technology (Nu.QⓇ).measures H3K27me3 levels in biological fluids. EZH2 inhibitors (EZH2i) are being tested in clinical trials. We hypothesize that epigenetic reprogramming via EZH2i improves the efficacy of Carboplatin in AVPC and that EZH2i activity can be measured via both cellular-and cell-free nucleosomal H3K27me3 (cf-H3K27me3) levels. Methods: We studied the expression of PRC2 genes in clinical prostate cancer cohorts (bioinformatics) . We determined the effect of EZH2i on cellular-and cf-H3K27me3 levels. We measured dose-dependent effects of Carboplatin with/without EZH2i on AVPC cell viability (IC50) . We used RNA-Seq to study how EZH2i modulates gene expression in AVPC cells.\u003Cbr>Results: PRC2 genes were significantly up-regulated in AVPC vs other prostate cancer types. EZH2i reduced both cellular and cf-H3K27me3 levels. EZH2i significantly reduced Carboplatin IC50. EZH2i reduced the expression of DNA repair genes and increased the expression of p53-dependent pro-apoptotic factors. Conclusions: EZH2i plus Carboplatin is a promising combination treatment for AVPC. |  | ARTICLE HISTORY\u003Cbr>Received 7 June 2024 Accepted 10 January 2025\u003Cbr>KEYWORDS\u003Cbr>EZH2; epigenetics; Tazemetostat; personalized epigenetic therapies; Carboplatin; aggressive variant prostate cancer; neuroendocrine prostate cancer |\n| 1. Introduction\u003Cbr>Prolonged hormonal therapies induce phenotypic plasticity and multi-drug resistance in advanced prostate cancer [1] . Malignancies emerging from this phenomenon are androgen receptor (AR)-negative or AR-indifferent and have been classified as: (I) neuroendocrine prostate cancers (NEPCs), which express typical trans-differentiation markers (e.g., synaptophysin, FOXA2 [2]); (II) double negative prostate cancers, which are both AR-negative/-indifferent and NEPCnegative [3]; (III) aggressive-variant prostate cancers (AVPCs), which include adenocarcinomas and NEPCs that meet clinical and molecular criteria for enhanced metastatic ability and for androgen indiffer","cbCaigFs46pai3oS","https://ap.wps.com/l/cbCaigFs46pai3oS","pdf",4444924,"English","# Abstract\n# Introduction\n## Prostate cancer phenotypic plasticity and AVPC classification\n## PRC2/EZH2 biology and rationale for EZH2 inhibition","[{\"question\":\"Why are EZH2 inhibitors considered in aggressive-variant prostate cancer?\",\"answer\":\"PRC2 promotes AVPC progression through H3K27me3, and EZH2 is the PRC2 catalytic subunit. The study hypothesizes that inhibiting EZH2 can epigenetically improve response to Carboplatin.\"},{\"question\":\"How does EZH2 inhibition affect H3K27me3 levels?\",\"answer\":\"EZH2 inhibitors reduce both cellular and cell-free nucleosomal H3K27me3 levels, linking EZH2i activity to measurable epigenetic changes.\"},{\"question\":\"What is the main therapeutic outcome when combining EZH2 inhibition with Carboplatin?\",\"answer\":\"The combination is reported as promising because EZH2 inhibition significantly reduces Carboplatin IC50 and shifts gene expression toward reduced DNA repair and increased p53-dependent pro-apoptotic factors.\"}]","EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines | PDF",1790187603,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/797bc123fd781c77e1b98c85bf69c67b.webp",983,1280,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e2e2acce1fb4edb4ff688c273a7850c.webp",982,1278,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90a977b76cce16a290925ade34bdbe3a.webp",981,1277,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83cebd7d5d12e43966625c3e5933df37.webp",980,1276]